Gujarat Themis Biosyn Limited
Gujarat Themis Biosyn Limited engages in the manufacture of pharmaceuticals and medicinal chemicals in India. The company offers bulk drugs on job work basis in India. Its products include Rifamycin-S, an intermediate for the treatment of tuberculosis, Mycobacterium avium complex, leprosy, and Legionnaires' disease; Rifamycin-O for the treatment of traveler's diarrhea, irritable bowel syndrome, a… Read more
Gujarat Themis Biosyn Limited (GUJTHEM) - Total Assets
Latest total assets as of September 2025: ₹3.77 Billion INR
Based on the latest financial reports, Gujarat Themis Biosyn Limited (GUJTHEM) holds total assets worth ₹3.77 Billion INR as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Gujarat Themis Biosyn Limited - Total Assets Trend (2022–2025)
This chart illustrates how Gujarat Themis Biosyn Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Gujarat Themis Biosyn Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Gujarat Themis Biosyn Limited's total assets of ₹3.77 Billion consist of 17.3% current assets and 82.8% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₹0.00 | 3.9% |
| Accounts Receivable | ₹314.51 Million | 10.4% |
| Inventory | ₹50.46 Million | 1.7% |
| Property, Plant & Equipment | ₹0.00 | 0.0% |
| Intangible Assets | ₹1.59 Million | 0.1% |
| Goodwill | ₹0.00 | 0.0% |
Asset Composition Trend (2022–2025)
This chart illustrates how Gujarat Themis Biosyn Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Gujarat Themis Biosyn Limited's current assets represent 17.3% of total assets in 2025, a decrease from 64.0% in 2022.
- Cash Position: Cash and equivalents constituted 3.9% of total assets in 2025, up from 0.2% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is accounts receivable at 10.4% of total assets.
Gujarat Themis Biosyn Limited Competitors by Total Assets
Key competitors of Gujarat Themis Biosyn Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Gujarat Themis Biosyn Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Gujarat Themis Biosyn Limited generates 0.50x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Gujarat Themis Biosyn Limited generates $ 16.19 in net profit.
Gujarat Themis Biosyn Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.47 | 2.53 | 2.99 |
| Quick Ratio | 1.27 | 2.30 | 2.59 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₹174.10 Million | ₹ 315.68 Million | ₹ 320.02 Million |
Gujarat Themis Biosyn Limited - Advanced Valuation Insights
This section examines the relationship between Gujarat Themis Biosyn Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 18.55 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | 36.3% |
| Total Assets | ₹3.01 Billion |
| Market Capitalization | $96.78 Million USD |
Valuation Analysis
Below Book Valuation: The market values Gujarat Themis Biosyn Limited's assets below their book value (0.03 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Gujarat Themis Biosyn Limited's assets grew by 36.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Gujarat Themis Biosyn Limited (2022–2025)
The table below shows the annual total assets of Gujarat Themis Biosyn Limited from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | ₹3.01 Billion | +36.27% |
| 2024-03-31 | ₹2.21 Billion | +32.94% |
| 2023-03-31 | ₹1.66 Billion | +35.78% |
| 2022-03-31 | ₹1.23 Billion | -- |